Lenvatinib + Everolimus
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Renal Cell Carcinoma
Conditions
Metastatic Renal Cell Carcinoma
Trial Timeline
Aug 5, 2010 → Feb 8, 2018
NCT ID
NCT01136733About Lenvatinib + Everolimus
Lenvatinib + Everolimus is a phase 1/2 stage product being developed by Eisai for Metastatic Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01136733. Target conditions include Metastatic Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Renal Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03324373 | Phase 1 | Completed |
| NCT03245151 | Phase 1/2 | Completed |
| NCT03173560 | Phase 2 | Completed |
| NCT02915783 | Phase 2 | Completed |
| NCT02454478 | Phase 1 | Completed |
| NCT01136733 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Renal Cell Carcinoma